lymphoma
Conditions
Interventions
germinal center(GC))-LME:Treat patients with a regimen containing vepostuzumab.
mesenchymal(MS)-LME:Treat patients with a regimen containing vepostuzumab.
inflammatory(IN)-LME:Treat patients with a regimen containing vepostuzumab.
immune depleted(DP)-LME:Treat patients with a regimen containing vepostuzumab.
Sponsors
the First Affiliated Hospital of Xi’an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) In patients with newly diagnosed DLBCL confirmed by tumor histopathology, at least one lesion must exhibit an axis measurement exceeding 1.5 cm; (2) Participants must be aged between 18 and 80 years, irrespective of gender, at the time of providing informed consent; (3) The ECOG performance status score should range from 0 to 2 points; (4) Polatuzumab vedotin is to be included in the treatment regimen.
Exclusion criteria
Exclusion criteria: Subjects who fulfill any of the following criteria are ineligible for study enrollment: (1) have previously undergone systemic or local therapies, including chemotherapy or autologous stem cell transplantation; (2) possess a prior history of other malignancies, with the exception of skin basal cell carcinoma and cervical carcinoma in situ; (3) present with uncontrolled cardiovascular and cerebrovascular diseases, serious infectious conditions, etc.; (4) exhibit lymphoma involvement in the central nervous system; (5) demonstrate a left ventricular ejection fraction < 50%; (6) include individuals with mental health disorders or others known or suspected to be unable to fully adhere to the study protocol; (7) are pregnant or breastfeeding women; (8) have confirmed human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infections as indicated by positive polymerase chain reaction (PCR); (9) suffer from other concurrent and uncontrolled medical conditions that the investigator deems may impact patient participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective response rate; | — |
Countries
China
Contacts
Public ContactLi Miaojing
the First Affiliated Hospital of Xi’an Jiaotong University
Outcome results
None listed